Astera Labs, Inc. Stock 12‑Month Price Target Cut to $409.45, Implies 75% Upside

What happened

Astera Labs, Inc.’s average 12-month stock price target fell from $414.45 to $409.45, based on estimates from 20 analysts. The revised target implies approximately 75% upside from the Nov. 3 closing price. Across 25 analysts, the consensus rating remains Buy, with 17 Buys, eight Holds and no Sells.

Confirmed

Global impact / market context

The lower average target signals a modest reduction in analysts’ expected value for Astera Labs shares, even as the reported target still implies substantial upside from the cited closing price. A target is a forecast, not a promised return, and does not establish future company sales or profits.

Analyst inference

Analysts’ target estimates range from $300 to $500 per share, showing meaningful disagreement about the stock’s potential value. The Buy consensus is unchanged, but it combines different views: eight analysts recommend Hold, while none recommend Sell; the article gives no reason for the target cut.

Confirmed

What to watch

1. Future analyst target changes could show whether the lower average target is an isolated revision or part of a broader shift in expectations for Astera Labs. Analyst inference
2. The article reports no change to the Buy consensus; a later rating tally would indicate whether recommendations shift alongside price targets. Analyst inference
3. The cited 75% potential upside is calculated from the Nov. 3 closing price; compare any future target with its stated reference price before interpreting the implied return. Confirmed

Evidence

• Original source link unavailable